Armistice Capital Master Fund Ltd.
CIK 0001633584 Name as filed on the most recent filing
Filed as Armistice Capital Master Fund Ltd. (191)
1,268 transaction lines · from 191 filings · filed 2017-05-09 to 2023-06-28 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Avalo Therapeutics, Inc. 72 filings
- ISSUER Eyegate Pharmaceuticals Inc 16 filings
- ISSUER Aytu Bioscience, Inc 4 filings
- ISSUER ReShape Lifesciences Inc. 23 filings
- ISSUER Cyclo Therapeutics, Inc. 7 filings
- ISSUER Tenax Therapeutics, Inc. 5 filings
- ISSUER Vaxart, Inc. 13 filings
- ISSUER Amag Pharmaceuticals, Inc. 6 filings
- ISSUER Valeritas Holdings Inc. 11 filings
- ISSUER Onconova Therapeutics, Inc. 1 filings
- ISSUER Innovus Pharmaceuticals, Inc. 1 filings
- ISSUER Achieve Life Sciences, Inc. 2 filings
- ISSUER Del Frisco's Restaurant Group, Inc. 19 filings
- ISSUER Bio-Path Holdings Inc 1 filings
- ISSUER Vical Inc 7 filings
- ISSUER Pain Therapeutics Inc 2 filings
- ISSUER Alimera Sciences Inc 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2023-06-27 |
Avalo Therapeutics, Inc. AVTX |
S, Open-market sale | 937,404 disposed | 0.52 | 486,887.64 | Form 4, filing 0000899243-23-016659 | |
| 2023-06-26 |
Avalo Therapeutics, Inc. AVTX |
S, Open-market sale | 2,746,138 disposed | 0.61 | 1,682,009.52 | Form 4, filing 0000899243-23-016659 | |
| 2023-02-07 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 450,000 acquired | Not reported | Not priced | Form 4, filing 0000899243-23-004412 | |
| 2022-03-14 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 100,000 acquired | 0.65 | 64,940.00 | Form 4, filing 0000899243-22-010904 | |
| 2022-03-11 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 100,000 acquired | 0.69 | 68,780.00 | Form 4, filing 0000899243-22-010904 | |
| 2022-03-10 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 26,000 acquired | 0.70 | 18,226.00 | Form 4, filing 0000899243-22-010904 | |
| 2022-03-07 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 325,000 acquired | 0.66 | 213,330.00 | Form 4, filing 0000899243-22-009744 | |
| 2022-03-04 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 135,000 acquired | 0.70 | 95,107.50 | Form 4, filing 0000899243-22-009744 | |
| 2022-03-03 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 50,000 acquired | 0.71 | 35,695.00 | Form 4, filing 0000899243-22-009744 | |
| 2022-02-25 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 40,000 acquired | 0.79 | 31,716.00 | Form 4, filing 0000899243-22-008145 | |
| 2022-02-24 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 100,000 acquired | 0.80 | 80,090.00 | Form 4, filing 0000899243-22-008145 | |
| 2022-02-22 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 83,000 acquired | 0.77 | 64,076.00 | Form 4, filing 0000899243-22-007249 | |
| 2022-02-18 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 55,000 acquired | 0.82 | 45,237.50 | Form 4, filing 0000899243-22-007249 | |
| 2022-02-17 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 150,000 acquired | 0.82 | 122,250.00 | Form 4, filing 0000899243-22-007249 | |
| 2022-01-20 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 12,000 acquired | 0.85 | 10,208.40 | Form 4, filing 0000899243-22-002693 | |
| 2022-01-19 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 93,700 acquired | 0.88 | 82,053.09 | Form 4, filing 0000899243-22-002693 | |
| 2022-01-18 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 206,300 acquired | 0.88 | 182,224.79 | Form 4, filing 0000899243-22-002693 | |
| 2022-01-14 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 85,000 acquired | 0.93 | 78,973.50 | Form 4, filing 0000899243-22-002025 | |
| 2022-01-13 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 312,700 acquired | 1.00 | 314,013.34 | Form 4, filing 0000899243-22-002025 | |
| 2022-01-12 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 57,300 acquired | 1.04 | 59,781.09 | Form 4, filing 0000899243-22-002025 | |
| 2022-01-11 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 16,003 acquired | 0.96 | 15,342.08 | Form 4, filing 0000899243-22-001618 | |
| 2022-01-10 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 491,097 acquired | 0.99 | 484,614.52 | Form 4, filing 0000899243-22-001618 | |
| 2022-01-07 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 137,900 acquired | 1.04 | 142,974.72 | Form 4, filing 0000899243-22-001618 | |
| 2021-09-17 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 5,454,545 acquired | 2.20 | 11,999,999.00 | Form 4, filing 0000899243-21-036402 | |
| 2021-09-16 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 150,000 acquired | 2.28 | 341,955.00 | Form 4, filing 0000899243-21-036402 | |
| 2021-09-15 |
Avalo Therapeutics, Inc. AVTX |
P, Open-market purchase | 95,455 acquired | 2.26 | 215,947.85 | Form 4, filing 0000899243-21-036402 | |
| 2021-08-18 |
Cerecor Inc. CERC |
P, Open-market purchase | 20,000 acquired | 2.78 | 55,550.00 | Form 4, filing 0000899243-21-033505 | |
| 2021-08-16 |
Cerecor Inc. CERC |
P, Open-market purchase | 30,000 acquired | 2.75 | 82,638.00 | Form 4, filing 0000899243-21-033505 | |
| 2021-08-06 |
Cerecor Inc. CERC |
P, Open-market purchase | 25,000 acquired | 2.83 | 70,630.00 | Form 4, filing 0001567619-21-014631 | |
| 2021-08-05 |
Cerecor Inc. CERC |
P, Open-market purchase | 25,000 acquired | 2.77 | 69,295.00 | Form 4, filing 0001567619-21-014631 | |
| 2021-08-04 |
Cerecor Inc. CERC |
P, Open-market purchase | 100,000 acquired | 2.69 | 268,590.00 | Form 4, filing 0001567619-21-014631 | |
| 2021-08-02 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 192,775 disposed | 2.40 | 463,045.55 | Form 4, filing 0001567619-21-014361 | |
| 2021-07-30 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 68,188 disposed | 2.69 | 183,562.10 | Form 4, filing 0001567619-21-014361 | |
| 2021-07-29 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 400,000 disposed | 3.00 | 1,200,000.00 | Form 4, filing 0000899243-21-030722 | |
| 2021-07-28 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 375,443 disposed | 3.28 | 1,232,616.91 | Form 4, filing 0000899243-21-030722 | |
| 2021-07-27 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 729,114 disposed | 5.44 | 3,966,161.43 | Form 4, filing 0000899243-21-030722 | |
| 2021-07-27 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 581,614 disposed | 3.80 | 2,209,551.59 | Form 4, filing 0000899243-21-030722 | |
| 2021-07-27 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 532,069 disposed | 4.59 | 2,440,972.95 | Form 4, filing 0000899243-21-030722 | |
| 2021-07-27 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 461,797 disposed | 6.45 | 2,980,853.46 | Form 4, filing 0000899243-21-030722 | |
| 2021-07-27 |
Eyegate Pharmaceuticals Inc EYEG |
S, Open-market sale | 73,101 disposed | 7.06 | 516,107.68 | Form 4, filing 0000899243-21-030722 | |
| 2021-05-18 |
Cerecor Inc. CERC |
P, Open-market purchase | 22,000 acquired | 2.33 | 51,260.00 | Form 4, filing 0000919574-21-003782 | |
| 2021-05-18 |
Cerecor Inc. CERC |
P, Open-market purchase | 0 acquired | Not reported | Not priced | Form 4, filing 0000919574-21-003782 | |
| 2021-05-17 |
Cerecor Inc. CERC |
P, Open-market purchase | 30,000 acquired | 2.20 | 66,000.00 | Form 4, filing 0000919574-21-003782 | |
| 2021-05-17 |
Cerecor Inc. CERC |
P, Open-market purchase | 0 acquired | Not reported | Not priced | Form 4, filing 0000919574-21-003782 | |
| 2021-05-14 |
Cerecor Inc. CERC |
P, Open-market purchase | 128,000 acquired | 2.15 | 275,200.00 | Form 4, filing 0000919574-21-003782 | |
| 2021-05-14 |
Cerecor Inc. CERC |
P, Open-market purchase | 0 acquired | Not reported | Not priced | Form 4, filing 0000919574-21-003782 | |
| 2021-01-08 |
Cerecor Inc. CERC |
P, Open-market purchase | 2,500,000 acquired | 2.60 | 6,500,000.00 | Form 4, filing 0000919574-21-000248 | |
| 2021-01-08 |
Cerecor Inc. CERC |
P, Open-market purchase | 0 acquired | Not reported | Not priced | Form 4, filing 0000919574-21-000248 | |
| 2021-01-06 |
Eyegate Pharmaceuticals Inc EYEG |
P, Open-market purchase | 1,531,101 acquired | 5.22 | 8,000,002.72 | Form 4, filing 0000919574-21-000168 | |
| 2021-01-06 |
Eyegate Pharmaceuticals Inc EYEG |
P, Open-market purchase | 0 acquired | Not reported | Not priced | Form 4, filing 0000919574-21-000168 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Armistice Capital Master Fund Ltd., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001633584
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6